Table 1.
Enrollment characteristics according to treatment group
| Characteristic | FTC-TDF (n=1308) | TDF (n=1271) | Placebo (n=1345) |
|---|---|---|---|
| Age (years) | |||
| Mean (range) | 35 (18-64) | 35 (18-64) | 35 (18-64) |
| <25 | 9% | 9% | 9% |
| 25-34 | 43% | 44% | 43% |
| 35-44 | 33% | 33% | 34% |
| ≥45 | 15% | 14% | 14% |
| Male | 67% | 66% | 63% |
| Serum Creatinine (mg/dL) | 0.79 ± 0.15 | 0.79 ± 0.15 | 0.78 ± 0.15 |
| eGFR (mL/minute/1.73 m2) | 129 ± 17 | 129 ± 16 | 129 ± 16 |
| eGFR <90 mL/minute/1.73 m2 | 98% | 98% | 98% |
| Weight (kg) | 61 ± 9 | 61 ± 10 | 61± 10 |
| Body Mass Index | |||
| <18.5 | 6% | 5% | 4% |
| 18.5-24.9 | 78% | 79% | 79% |
| 25-29.9 | 13% | 12% | 13% |
| ≥30 | 3% | 4% | 4% |
| Systolic blood pressure ≥140mmHg | 5% | 5% | 6% |
Unless stated, statistics are mean ± standard deviations for continuous covariates and percentages for categorical covariates. For the present analysis, glomerular filtration rate (eGFR) was calculated from serum creatinine using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) Equation, although the Cockcroft-Gault equation was used for safety monitoring during the study. FTC denotes emtricitabine TDF denotes tenofovir disoproxil fumarate.